Diseases Affecting Bone Quality: Beyond Osteoporosis

Overview

Journal Clin Orthop Relat Res

Publisher Wolters Kluwer

Specialty Orthopedics

Date 2010 Nov 26

PMID 21107923

Citations 27

Authors

Aasis Unnanuntana

Brian J Rebolledo

M Michael Khair

Edward F DiCarlo

Joseph M Lane

Affiliations

Soon will be listed here.

Abstract

Background: Bone quantity, quality, and turnover contribute to whole bone strength. Although bone mineral density, or bone quantity, is associated with increased fracture risk, less is known about bone quality. Various conditions, including disorders of mineral homeostasis, disorders in bone remodeling, collagen disorders, and drugs, affect bone quality.

Questions/purposes: The objectives of this review are to (1) identify the conditions and diseases that could adversely affect bone quality besides osteoporosis, and (2) evaluate how these conditions influence bone quality.

Methods: We searched PubMed using the keywords "causes" combined with "secondary osteoporosis" or "fragility fracture." After identifying 20 disorders/conditions, we subsequently searched each condition to evaluate its effect on bone quality.

Results: Many disorders or conditions have an effect on bone metabolism, leading to fragility fractures. These disorders include abnormalities that disrupt mineral homeostasis, lead to an alteration of the mineralization process, and ultimately reduce bone strength. The balance between bone formation and resorption is also essential to prevent microdamage accumulation and maintain proper material and structural integrity of the bone. As a result, diseases that alter the bone turnover process lead to a reduction of bone strength. Because Type I collagen is the most abundant protein found in bone, defects in Type I collagen can result in alterations of material property, ultimately leading to fragility fractures. Additionally, some medications can adversely affect bone.

Conclusions: Recognizing these conditions and diseases and understanding their etiology and pathogenesis is crucial for patient care and maintaining overall bone health.

Citing Articles

Microbial Extracellular Vesicles in Host-Microbiota Interactions.

Abubaker S, Miri S, Mottawea W, Hammami R Results Probl Cell Differ. 2024; 73:475-520.

PMID: 39242390 DOI: 10.1007/978-3-031-62036-2_19.

Inhibition of cysteine protease disturbs the topological relationship between bone resorption and formation in vitro.

Ono S, Tsuji N, Sakamoto T, Oguchi S, Nakamura T, Hoshi K J Bone Miner Metab. 2024; 42(2):166-184.

PMID: 38376670 PMC: 10982105. DOI: 10.1007/s00774-023-01489-w.

Editorial: Genetic and molecular determinants in bone health and diseases.

Rossi M, Lowery J, Del Fattore A Front Endocrinol (Lausanne). 2024; 15:1347765.

PMID: 38304462 PMC: 10832011. DOI: 10.3389/fendo.2024.1347765.

Differential effects of teriparatide, denosumab and zoledronate on hip structural and mechanical parameters in osteoporosis; a real-life study.

Jaarah N, Lam C, Lodhia N, Dulnoan D, Moore A, Hampson G J Endocrinol Invest. 2024; 47(7):1667-1677.

PMID: 38191946 PMC: 11196340. DOI: 10.1007/s40618-023-02280-4.

Exploring the impact of naltrexone on the THBS1/eNOS/NO pathway in osteoporotic bile duct-ligated rats.

Hosseini-Fard S, Etemad-Moghadam S, Alaeddini M, Dehpour A, Emamgholipour S, Golestani A Sci Rep. 2024; 14(1):48.

PMID: 38167957 PMC: 10761994. DOI: 10.1038/s41598-023-50547-w.

References

Sahni S, Hannan M, Gagnon D, Blumberg J, Cupples L, Kiel D . Protective effect of total and supplemental vitamin C intake on the risk of hip fracture--a 17-year follow-up from the Framingham Osteoporosis Study. Osteoporos Int. 2009; 20(11):1853-61. PMC: 2766028. DOI: 10.1007/s00198-009-0897-y. View

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner J . Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008; 9(9):840-9. DOI: 10.1016/S1470-2045(08)70204-3. View

Yao W, Cheng Z, Busse C, Pham A, Nakamura M, Lane N . Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 2008; 58(6):1674-86. PMC: 3892702. DOI: 10.1002/art.23454. View

DENT C, Richens A, Rowe D, Stamp T . Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J. 1970; 4(5727):69-72. PMC: 1819593. DOI: 10.1136/bmj.4.5727.69. View

Jilka R, Weinstein R, Parfitt A, Manolagas S . Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res. 2007; 22(10):1492-501. DOI: 10.1359/jbmr.070518. View

Vestergaard P, Rejnmark L, Mosekilde L . Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006; 79(2):76-83. DOI: 10.1007/s00223-006-0021-7. View

Schuit S, van der Klift M, Weel A, de Laet C, Burger H, Seeman E . Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004; 34(1):195-202. DOI: 10.1016/j.bone.2003.10.001. View

Goh S, Yang K, Koh J, Wong M, Chua S, Chua D . Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007; 89(3):349-53. DOI: 10.1302/0301-620X.89B3.18146. View

Odvina C, Zerwekh J, Rao D, Maalouf N, Gottschalk F, Pak C . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2004; 90(3):1294-301. DOI: 10.1210/jc.2004-0952. View

10.

Eichelbaum M, Ekbom K, Bertilsson L, Ringberger V, Rane A . Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol. 1975; 8(5):337-41. DOI: 10.1007/BF00562659. View

11.

Lanyon L . Using functional loading to influence bone mass and architecture: objectives, mechanisms, and relationship with estrogen of the mechanically adaptive process in bone. Bone. 1996; 18(1 Suppl):37S-43S. DOI: 10.1016/8756-3282(95)00378-9. View

12.

Schultheis L . The mechanical control system of bone in weightless spaceflight and in aging. Exp Gerontol. 1991; 26(2-3):203-14. DOI: 10.1016/0531-5565(91)90012-b. View

13.

Conney A . Pharmacological implications of microsomal enzyme induction. Pharmacol Rev. 1967; 19(3):317-66. View

14.

Landa J, Margolis N, Di Cesare P . Orthopaedic management of the patient with osteopetrosis. J Am Acad Orthop Surg. 2007; 15(11):654-62. DOI: 10.5435/00124635-200711000-00004. View

15.

Vieth R . Vitamin D toxicity, policy, and science. J Bone Miner Res. 2008; 22 Suppl 2:V64-8. DOI: 10.1359/jbmr.07s221. View

16.

Brown S, Guise T . Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr. 2009; 19(1):47-60. PMC: 2762110. DOI: 10.1615/critreveukargeneexpr.v19.i1.20. View

17.

Scane A, Sutcliffe A, Francis R . Osteoporosis in men. Baillieres Clin Rheumatol. 1993; 7(3):589-601. DOI: 10.1016/s0950-3579(05)80081-0. View

18.

Hollis B . Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005; 135(2):317-22. DOI: 10.1093/jn/135.2.317. View

19.

Le Parc J, Plantin P, Jondeau G, Goldschild M, Albert M, Boileau C . Bone mineral density in sixty adult patients with Marfan syndrome. Osteoporos Int. 2000; 10(6):475-9. DOI: 10.1007/s001980050257. View

20.

Sillence D, Senn A, Danks D . Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979; 16(2):101-16. PMC: 1012733. DOI: 10.1136/jmg.16.2.101. View